AAAAAA

   
Results: 1-13 |
Results: 13
Prostate cancer chemotherapy - Closing out a century and opening a new one
Authors: Kamradt, JM Pienta, KJ
Citation: Jm. Kamradt et Kj. Pienta, Prostate cancer chemotherapy - Closing out a century and opening a new one, CONT CANC R, 2001, pp. 415-431
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study
Authors: Williams, JF Muenchen, HJ Kamradt, JM Korenchuk, S Pienta, KJ
Citation: Jf. Williams et al., Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study, PROSTATE, 44(4), 2000, pp. 275-278
Hormonal manipulation of prostate cancer
Authors: Kamradt, JM Pienta, KJ
Citation: Jm. Kamradt et Kj. Pienta, Hormonal manipulation of prostate cancer, CONT ENDOC, 2000, pp. 293-311
New paradigms in the management of hormone refractory disease
Authors: Kamradt, JM Pienta, KJ
Citation: Jm. Kamradt et Kj. Pienta, New paradigms in the management of hormone refractory disease, CURR CLIN U, 2000, pp. 289-303
Rational use of chemotherapy - It is not just rat poison
Authors: Kamradt, JM Klein, EA Pienta, KJ
Citation: Jm. Kamradt et al., Rational use of chemotherapy - It is not just rat poison, UROL CLIN N, 26(2), 1999, pp. 275
Oral chemotherapy for hormone refractory prostate cancer - The University of Michigan experience
Authors: Kamradt, JM Smith, DC Pienta, KJ
Citation: Jm. Kamradt et al., Oral chemotherapy for hormone refractory prostate cancer - The University of Michigan experience, UROL CLIN N, 26(2), 1999, pp. 333
Current chemotherapy regimens - What oncologists are using
Authors: Kamradt, JM Pienta, KJ
Citation: Jm. Kamradt et Kj. Pienta, Current chemotherapy regimens - What oncologists are using, UROL CLIN N, 26(2), 1999, pp. 419
Novel molecular targets for prostate cancer therapy
Authors: Kamradt, JM Pienta, KJ
Citation: Jm. Kamradt et Kj. Pienta, Novel molecular targets for prostate cancer therapy, SEMIN ONCOL, 26(2), 1999, pp. 234-243
Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line
Authors: Panvichian, R Orth, K Pilat, MJ Day, ML Day, KC Yee, C Kamradt, JM Pienta, KJ
Citation: R. Panvichian et al., Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line, UROLOGY, 54(4), 1999, pp. 746-752
Oral chemotherapy in the treatment of hormone-refractory prostate cancer
Authors: Pienta, KJ Kamradt, JM Smith, DC
Citation: Kj. Pienta et al., Oral chemotherapy in the treatment of hormone-refractory prostate cancer, DRUGS, 58, 1999, pp. 127-131
Mechanisms of androgen resistance in prostate cancer
Authors: Kamradt, JM Pilat, MJ Pienta, KJ
Citation: Jm. Kamradt et al., Mechanisms of androgen resistance in prostate cancer, MOL UROL, 2(3), 1998, pp. 257-262
Carboplatin-induced cell death in model prostate cancer systems
Authors: Yee, CS Kamradt, JM Nielsen, LC Panvinchian, R Pienta, KJ
Citation: Cs. Yee et al., Carboplatin-induced cell death in model prostate cancer systems, ANTICANC R, 18(6A), 1998, pp. 4475-4482
Hormone resistance in prostate cancer
Authors: Pilat, MJP Kamradt, JM Pienta, KJ
Citation: Mjp. Pilat et al., Hormone resistance in prostate cancer, CANC METAST, 17(4), 1998, pp. 373-381
Risultati: 1-13 |